Pfizer's new crown oral drug Paxlovid is $529 per course of treatment

On November 18, local time, Pfizer announced that the U.

Paxlovid: An emergency use authorization has been applied to the FDA, USD 529 for a course of treatment

Paxlovid is a compound preparation of SARS-CoV-2-3CL protease inhibitor PF-07321332 and low-dose antiviral drug ritonavir.

On November 5, Pfizer disclosed preliminary observations on the results of the Paxlovid study.

In this announcement, Pfizer stated that according to the agreement, the U.

In addition, Pfizer also disclosed in the announcement that it has signed pre-purchase agreements with several countries and has initiated bilateral contacts with about 100 countries around the world

Pfizer stated that it has begun to seek authorization in many countries and regions including the United Kingdom, Australia, New Zealand and South Korea, and plans to submit further international applications

Merck's first oral drug for the new crown: a course of treatment is about US$709

On November 4, the British Medicines and Health Products Administration (MHRA) announced the approval of the oral antiviral drug Monupiravir (Molnupiravir) developed by Merck and Ridgeback for the treatment of COVID-19 for the treatment of mild to moderate COVID- 19 adult patients

As of October, the UK has purchased 480,000 courses of Molnupiravir

It is worth mentioning that in June of this year, Merck signed an agreement with the US government.

For people in most countries in the world, US$709 is not a small sum

On October 27th, Merck and its partner Ridgeback announced that they had reached a treatment license agreement with the United Nations to give up patents in 105 low- and middle-income countries around the world to allow them to produce generic drugs

Merck also stated that it plans to adopt a tiered pricing strategy for developing countries